Phase I/II Study of Lenalidomide in Combination With Rituximab, Ifosfamide, Etoposide, and Carboplatin (RICER)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 03 Feb 2014
At a glance
- Drugs Lenalidomide (Primary) ; Carboplatin; Carmustine; Cytarabine; Etoposide; Ifosfamide; Melphalan; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 03 Feb 2014 Planned End Date changed from 1 Oct 2014 to 1 Dec 2014 ClinicalTrials.gov record.
- 03 Feb 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.